CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ HypothesisLecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research
Michael Mark proposes a new hypothesis that may explain the observed CV benefit of empagliflozin, involving increased haematocrit and higher ketone bodies as a potent alternative energy source.
This lecture was recorded at the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016.
Video navigation menu
- A recap of the study design of the EMPA-REG OUTCOME study 0:41
- A closer look at the mortality benefit seen with empagliflozin treatment as compared with placebo 2:07
- Speculating on the underlying mechanism of the CV benefit seen with empagliflozin treatment 4:15
- A new hypothesis emerges: empagliflozin increases oxygen delivery to organs by increasing hematocrit 11:03
- Part two of the new hypothesis, involving increased ketone bodies featuring as a 'superfuel' 16:08
- A covariate analysis of the EMPA-REG OUTCOME data provides evidence for the new hypothesis 23:13